Participated · Series D · Sep 2024

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.

Participated · Series A · Dec 2022

Founded in 2020, Paywatch provides an earned wage access (EWA) service that lets employees withdraw a portion of their accrued salary instantly, reducing dependence on short-term credit between paydays. The company has processed more than US$200 million in EWA transactions and supports large enterprise clients such as Genting Group, DFI Retail (Guardian), Shangri-La Hotels, CP Group (Lotus’s), Lotte Group, Wilmar and Hyundai. Operating across six markets—Malaysia, the Philippines, Indonesia, Singapore, Hong Kong and South Korea—Paywatch embeds its solution directly into employer payroll and HR systems. Management plans to transform the business into a “NeoFi” platform by adding micro-insurance, cross-border payments and employee rewards, all delivered through AI-driven tooling. Partnerships with the UNCDF and the ILO are cited to underscore responsible product design. The firm argues that its offering lowers employee churn and boosts productivity for employers while improving workers’ financial outcomes. Credit lines from global banks complement venture funding, enabling a capital-light growth model that supports rapid regional expansion.

Participated · Series C · Feb 2022

Epirus develops counter-drone systems centered on its Leonidas platform, which beams high-powered electromagnetic pulses at drones as it moves across the battlefield. The company has won multiple U.S. military contracts, including a $66 million Army deal awarded in 2023. Epirus plans to use new funding to expand into international and commercial markets, grow its team, improve supply chain resiliency, and open a simulation center in Oklahoma to train soldiers. Financially, Epirus has raised an oversubscribed $250 million Series D and says its valuation is over $1 billion. The firm was previously valued at $1.35 billion after a $200 million Series C in 2022, and Bloomberg reported the new round was being raised at a lower valuation than that Series C. To date, Epirus has raised more than $550 million in total. Epirus designs solid‑state, software‑defined directed energy systems and a machine‑intelligent SmartPower platform to optimize power efficiency in defense and commercial applications. Its flagship Leonidas high‑power microwave (HPM) system and the portable Leonidas Pod create a layered counter‑electronics capability against hostile drones and electronic threats. The company has multiple product lines in development and says recent DARPA and Army Applications Laboratory contracts validate its defense market traction. In the past year Epirus more than doubled its workforce and opened a Corporate Headquarters in Torrance, California to support accelerated growth. Founded in 2018, Epirus emphasizes rapid innovation and plans to expand its team and commercial applications for its technology. Financially, the company announced a $200 million Series C, bringing total financing to date to $287 million and valuing the business at $1.35 billion. Epirus builds software-defined high-powered microwave (HPM) products and directed-energy systems, with SmartPower power-management technology at the center of its product roadmap. The company is bringing its flagship Leonidas C-UAS system to market in early 2021 and is developing additional directed-energy solutions for defense and commercial markets. Epirus has a strategic supplier agreement with Northrop Grumman to provide an EMP capability as a component of Northrop Grumman’s C-UAS systems-of-systems offering. L3Harris Technologies is partnering with and investing in Epirus to create greater power efficiencies within some of its systems. The company has expanded its footprint with an office in Tysons Corner and plans to hire roughly 100 roles in 2021 and double headcount again in 2022, with further expansion across Los Angeles, Virginia, and the Midwest. Recent financings support its manufacturing and scale-up plans for SmartPower and other products.

Participated · Series D · Feb 2022

Kallyope is a clinical-stage biotechnology company leveraging its proprietary Klarity™ therapeutic platform to discover and develop oral small-molecule therapeutics. Its programs focus on metabolism (including diabetes and obesity), gastrointestinal disease, and neurological disorders. Under a four-year, $8.2 million grant from the Bill & Melinda Gates Foundation, Kallyope will apply its gut-focused screening and validation capabilities to identify and characterize metabolites for interventions targeting environmental enteric dysfunction (EED) in undernourished pregnant and lactating women and mothers. The work will be conducted in collaboration with other institutions affiliated with the foundation. Kallyope will retain rights to develop compounds derived from the identified agents as possible therapeutics and as supplements in low-resource nations and other global regions. The effort is explicitly aimed at improving maternal, newborn, and child health in epicenters of the global food and nutrition crisis where EED contributes to stunting and poor infant outcomes. Kallyope has built a drug‑discovery platform that integrates sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to reveal gut‑brain biology. The company focuses on targeting gut and gut‑brain physiology with gut‑restricted molecules to increase the speed and probability of success in drug discovery. Its pipeline spans metabolism, immunology and inflammation, and central nervous system disorders. Over the past 13 months Kallyope advanced four compounds into the clinic across its two lead programs in Type 2 diabetes, obesity, and diseases of the gastrointestinal barrier. The company reports more than 20 programs and molecules in its broader pipeline. Headquartered at the Alexandria Center for Life Science in New York City, Kallyope was founded six years ago and has raised nearly $480 million to date. Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. Led by CEO Nancy Thornberry and founded by Charles Zuker, Tom Maniatis, and Richard Axel, the company integrates sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to understand gut-brain biology. Headquartered at the Alexandria Center for Life Science in New York City, Kallyope is advancing a broad portfolio of programs across gastrointestinal, CNS, and inflammatory disorders. Its lead program targets satiety circuits for weight loss, with clinical testing expected to begin later this year. A second program targeting gut barrier function with potential relevance for inflammatory bowel disease is anticipated to enter the clinic soon after. The company raised $112M in a Series C to advance its portfolio of programs and its first clinical trials. Kallyope is a New York City–based biotechnology company focused on identifying therapeutic opportunities involving the gut–brain axis. The company has developed a platform that enables a systematic approach to targeting gut–brain circuits with small molecules and has initiated multiple programs spanning metabolic, central nervous system, and gastrointestinal disorders. In addition to its internal small-molecule programs, Kallyope recently initiated a collaboration with Novo Nordisk focused on discovery of peptide therapeutics for obesity and diabetes. Kallyope raised a $21M expansion of its previously announced Series B, bringing the Series B total to $87M and total capital raised since inception to $131M. The company says it will use the additional funds to further advance its portfolio of programs targeting the gut–brain axis. Kallyope is headquartered at the Alexandria Center for Life Science in New York City and is led by CEO Nancy Thornberry; it was co-founded by Charles Zuker, Tom Maniatis and Richard Axel. Kallyope integrates sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to discover therapeutic opportunities involving the gut–brain axis. The company is led by CEO Nancy Thornberry and was co-founded by Charles Zuker, Tom Maniatis and Richard Axel. Initially Kallyope will focus on metabolic and neurological disorders with plans to expand into other disease areas involving the gut and gut–brain biology. The firm describes itself as a cross-disciplinary platform biotechnology company aiming to translate biological insights into transformational therapeutics. The company will use new funding to expand operations and scale its team. It expected to grow to nearly 60 employees by the end of 2018.

Participated · Series D · Aug 2021

Founded in 2014, Octane offers an end-to-end digital buying experience for powersports, RVs, boats, personal watercraft, and outdoor power equipment. Its platform pre-qualifies consumers online, routes them to dealerships for quick closings, and services the loans it originates. The company’s financing portal and underwriting engine have helped it originate more than $7 billion in loans, issue over $4.7 billion in asset-backed securities, and sell or commit to sell $3.3 billion of secured consumer loans since December 2023. Octane grew originations by more than 30 percent from Q3 2024 to Q3 2025 and operates on a GAAP-net-income-profitable basis. It works with 60 OEM partner brands and over 4,000 dealer partners, addressing markets worth a combined $150 billion. Recent product launches have further sped up customer acquisition for merchants and improved flexibility for borrowers. The company employs about 600 people across remote and hybrid roles.